Search research articles
Contact Us
Filters
Showing results (281-290 of 336) with videos related to
Page
of 34
Sort By:
Cancer Immunology, Immunotherapy : CII
|
March 24, 2026
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)
Veronica Mollica, Francesco Massari, Kazutoshi Fujita, et al.
Clinical Genitourinary Cancer
|
May 1, 2026
Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 study
Giandomenico Roviello, Martina Catalano, Elisabetta Gambale, et al.
Minerva Urology and Nephrology
|
April 23, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study)
Marco Maruzzo, Alexandr Poprach, Sebastiano Buti, et al.
JCO Global Oncology
|
October 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study
Francesco Massari, Matteo Rosellini, Bohuslav Melichar, et al.
Frontiers in Oncology
|
August 11, 2025
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study
Maria T Bourlon, Luca Galli, Enrique Grande, et al.
Targeted Oncology
|
September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII
|
July 2, 2024
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study
Carlo Messina, Martina Catalano, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII
|
November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
Ray Manneh Kopp, Francesco Massari, Enrique Grande, et al.
Immunotherapy
|
February 25, 2020
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study
Melissa Bersanelli, Sebastiano Buti, Giuseppe Luigi Banna, et al.
International Journal of Cancer
|
September 7, 2024
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)
Chiara Ciccarese, Thomas Büttner, Linda Cerbone, et al.
Page
of 34
Search research articles
Search
Showing results (281-290 of 336) with videos related to
Sort By:
Page
of 34
Cancer Immunology, Immunotherapy : CII
|
March 24, 2026
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)
Veronica Mollica, Francesco Massari, Kazutoshi Fujita, et al.
Clinical Genitourinary Cancer
|
May 1, 2026
Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 study
Giandomenico Roviello, Martina Catalano, Elisabetta Gambale, et al.
Minerva Urology and Nephrology
|
April 23, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study)
Marco Maruzzo, Alexandr Poprach, Sebastiano Buti, et al.
JCO Global Oncology
|
October 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study
Francesco Massari, Matteo Rosellini, Bohuslav Melichar, et al.
Frontiers in Oncology
|
August 11, 2025
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study
Maria T Bourlon, Luca Galli, Enrique Grande, et al.
Targeted Oncology
|
September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII
|
July 2, 2024
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study
Carlo Messina, Martina Catalano, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII
|
November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
Ray Manneh Kopp, Francesco Massari, Enrique Grande, et al.
Immunotherapy
|
February 25, 2020
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study
Melissa Bersanelli, Sebastiano Buti, Giuseppe Luigi Banna, et al.
International Journal of Cancer
|
September 7, 2024
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)
Chiara Ciccarese, Thomas Büttner, Linda Cerbone, et al.
Page
of 34